Condition: Diabetic Peripheral Neuropathy · Sponsor: Eli Lilly and Company
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Institute for Liver Health II dba Arizona Clinical Trials - Mesa | Chandler, Arizona, United States | — |
| Headlands Research - Scottsdale | Scottsdale, Arizona, United States | — |
| Orange Grove Family Practice | Tucson, Arizona, United States | — |
| Preferred Research Partners | Little Rock, Arkansas, United States | — |
| Hope Clinical Research, Inc. | Canoga Park, California, United States | — |
| Valley Clinical Trials, Inc. | Northridge, California, United States | — |
| Northern California Research - Sacramento | Sacramento, California, United States | — |
| CMR of Greater New Haven, LLC | Hamden, Connecticut, United States | — |
| Suncoast Research Group | Miami, Florida, United States | — |
| New Horizon Research Center | Miami, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Alliance for Multispecialty Research, LLC | Wichita, Kansas, United States | — |
+ 58 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.